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ABSTRACT OF THE DISSERTATION

The Role ofthe Pituitary-Adrenal Axis in G-CSF Therapy after
Neonatal Hj^oxia-Ischemia
by
Melissa Stephanie Charles
Doctor ofPhilosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, June 2012
Dr. Jiping Tang, Chairperson

Several reports indicate that the activity ofthe hypothalamic-pituitary-adrenal
axis(HPA)as measured by the increased level of adrenocorticotropic hormone(ACTH),
and corticosterone is increased after a brain insult. These hormones are the effectors

secreted respectively by the pituitary and adrenal glands. It has been shown that the

down-regulation of corticosterone levels can improve detrimental outcomes associated
with ischemic brain injuries. Neonatal hypoxia-ischemia(HI)is a devastating perinatal
event with a grim prognosis and limited therapeutic strategies. In recent studies,
granulocyte-colony stimulating factor(G-CSF)has shown promise in neonatal HI
investigations by improving neuromotor function and reducing apoptosis in the brain.
Furthermore, G-CSF is shown in the naive rat to regulate hormones ofthe HPA axis.
Therefore we hj^othesized that G-CSF may in part confer its neuroprotective properties

by influencing the pituitary-adrenal response after neonatal HI. To test our hypothesis,
metyrapone was administered to inhibit the release ofrodent specific glucocorticoid,
corticosterone, at the adrenal level. Dexamethasone, a synthetic glucocorticoid, was
administered to agonize the effects of corticosterone. Following the Rice-Vannucci
model, seven-day old rats(P7)were subjected to unilateral carotid ligation followed by

XI

2.5 hovirs of hypoxia. Our results show that both G-CSF and metyrapone significantly
reduced infarct volume via anti-apoptotic properties but lost its protective effect when
combined with dexamethasone. Additionally, G-CSF suppressed the increase of

corticosterone in the blood after HI. To investigate the mechanism by which G-CSF
modulated corticosterone synthesis, we evaluated its effect in adrenal cortical cells in

vitro. Our results indicate that G-CSF activated the JAK/PI3K/Alct/PDE3B pathway,
which in turn inhibited corticosterone synthesis. The inhibitors of JAK/PI3K/PDE3B

respectively Tyrphostin AG490,LY-294002, and 3-isobutyl-lmethylxanthine reversed
the inhibitory effect of G-CSF on corticosterone synthesis. We report that G-CSF was

neuroprotective in neonatal HI by reducing infarct volume, by suppressing the HIinduced increase ofthe Bax/Bcl-2 ratio, and by decreasing corticosterone at the adrenal
level via the JAK/PI3K/PDE3B pathway. Metyrapone was able to confer similar
neuroprotection as G-CSF while dexamethasone reversed the effects of G-CSF. In

conclusion, we show that reducing corticosterone was neuroprotective after neonatal HI,
which can be achieved by administering G-CSF.
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CHAPTER ONE
INTRODUCTION

Neonatal Hypoxia Ischemia

Neonatal hypoxia-ischemia(HI)is a major public health concern affecting both
term and preterm infants. It is characterized by exposure to low oxygen (hypoxia) and
decreased blood flow (ischemia) before, during, or after labor(Covey and Levison,
2006). This event is clinically defined as asphjocia and diagnosed as hypoxic-ischemic

encephalopathy (Zanelli et al, 2009). This clinical diagnosis is a tragic occurrence that
will afflict the infants with lifelong complications. For instance, inveterate conditions
such as cerebral palsy, mental retardation, and epilepsy are part ofthe grim prognosis, to
name a few (Hill and Volpe, 1989). Undoubtedly, this clinical event is increasingly
becoming burdensome not only for the patients, but also for the families, and

communities that care for them. This alarming problem is a financial issue as much as it
is a health complication. The lifelong projected costs for cerebral palsy alone are

estimated at $11.5 billion dollars in the United States(Derrick et al, 2007). For this
reason it has become imperative to investigate the causes and prevalence ofthis particular

condition in the population. Thereupon, one can establish how to approach an issue that
transcends medical science, public health, and the economy.

Epidemiology
HI is a major contributor to global child mortality and morbidity(Wachtel et al,

2011). HI has an overall incidence of 1-8 cases per 1000 births affecting 60% of preterm
infants(Vaimucci et al, 1999; Zanelli et al, 2009). With the increasing rate of premature

births in the United States(Callaghan et al, 2006),the projected costs associated with HI
are bound to increase. The chronic complications induced by HI affect a staggering 80%
ofsurvivors(Derrick et al, 2007; Zanelli et al, 2009). Because premature infants have an
underdeveloped cerebral circulation, a high density of excitatory neurons, and more
vulnerable neurons to reactive oxygen species and reactive nitrogen species, they
experience a more severe injury than foil-term infants(Takeoka et al, 2002). HI injury is

caused by a cascade of cytotoxic, oxidative and inflammatory stresses leading to brain
infarct, cerebral edema and neurological deficits(Vannucci et al, 2000).

Pathophysiology of HI
The development of brain injury in the immature brain can be divided in two
phases; acute phase, and the reperfosion (delayed) phase(Lai and Yang,2011). The
magnitude ofthe damage depends on the duration ofthe insult, the age ofthe infant,
reperfosion injury, and apoptosis(Zanelli et al, 2011). The initial effect ofthe depleted

oxygen concentration and reduced blood flow to the brain is energy failure (Vannucci et

al, 2005). The deprivation of glucose and the oxygen supply forces the cells to generate
energy via glycolysis through anaerobic respiration. This increases lactate production and
creates an acidic environment for the cells in the central nervous system(CNS)(Verklan,
2009). The deleterious effect ofthis primary energy failure impairs vascular

autoregulation, and the low pH halts the activity of cellular enzymes(Johnston et al,
2001). The sodium potassium ATP pump will then begin to fail, and cause an

intracellular accumulation ofsodium and calcimn ions(Barks and Silverstein, 1992). The
intracellular accumulation ofthese ions will cause the neurons to depolarize and release a

large amount of excitatory amino acid including glutamate(Wyatt et al, 1989). During
the reperfusion period, free radical damage will be initiated and the reactive oxygen
species will combine with the synthesized nitric oxide from glutamate receptor activation
to form toxic oxidants (Zanelli et al, 2011; Lai and Yang,2011; Pacher et al, 2007).

Calcium ion accumulation will activate a series of enzymes including endonucleases,
proteases and phospholipases that will damage and degrade protein, and DNA
(Ankarcrona et al, 1995). The latter will initiate the apoptotic and necrotic cascade which

will cause the cells to die. The releasing of pro-inflammatory cytokines by resident

immune cells ofthe CNS,and peripheral immune cells extravasating to the area ofinjury
will initiate the inflammatory response (ladecola and Anrather,2011; Ferriero, 2004). All
of which contribute to cerebral edema, subsequently leading to cell death. Early cell
death is t5q)ically necrotic and the continumn will make delayed cell death apoptotic
(Northington et al, 2001). Apoptosis will occur over days as a result of a less severe
insult, thus being a potential therapeutic target(Varklan, 2009). The penumbra, the area

surrounding the ischemic necrotic core, is not exposed to the same intensity of energy

failure placing these nemons in a critical stage where they can be recovered(Nakajima et
al, 2000; Pulera et al, 1998). Nevertheless, if these neurons are not rescued, within horns

the damage will eventually become irreversible as energy failure propagates towards the
rescuable cells in the penumbra.

Clinical Presentation

Within the first hours after the injury, the neonate will be unresponsive to sensory
input, and have a low level of consciousness(Volpe,2003; Samat and Samat, 1976).
Hypotonia, pupillary response may be intact depending on the severity and propagation
of brain injury. The infant will also exhibit abnormal respiratory patterns (Ferriero,
2004). In severe cases, 50-60% ofthose affected will have seizures. Subtle seizures can

be observed as rowing, bicycling, sucking movements, and apnea(Verklan, 2009).
Eventually, in the cases of moderate-severe injury, within 24-72 hours the infant will

succumb and deteriorate (Volpe,2003). Respiratory failure, deep stupor, and fixed pupils
may occur prior or immediately before death (ibid; Varklan,2009).

Therapeutic Options

In spite ofthe critical mortality, morbi^ty, and socio-economic hardship
accompanied with HI,therapeutic avenues are still lacking. Various anticonvulsants,
hypothermic treatments, and fluid and electrolytes management constitute current clinical

treatment, however,they have proven only some degree of success(Koenisgsberger,

I 2000; Zanelli et al, 2009). Due to the complexity oftiming, time-window of experimental
therapeutic options, and a lack ofthorough mechanistic studies, it has become crucial to

investigate novel and effective treatment plans for HI. Since the body's compensatory
response often contributes to the injmy, it has become increasingly imperative to

understand the physiological cascades that preclude the pathophysiological sequelae. For
example, one physiological response that is known to exacerbate injury, is the increase of
the activity ofthe hypothalamic-pituitary-adrenal axis.

Hypothalamic-Pituitary-Adrenal(HPA)Axis

The HPA axis is an intrinsic neuroendocrine regulatory system found in
vertebrates that allows the organism to respond and adapt to internal or extemal stressors

(Tsigos and Chrousos,2002). It is a system that helps the organism maintain homeostasis
particularly after a challenge and is vital for supporting normal physiological functioning
(KudieUca and Kirschbaum, 2005). For the interest of clarity, we chose a simplified

definition of stress as internal or extemal stimuli that can dismpt the biological
equilibrium. This can include a cerebrovascular event such as HI(Krugers et al, 2000;
Fassbender et al, 1994).

Anatomy ofthe HPA Axis

The brain circuits that initiate the stress response start in the paraventricular nuclei

(PVN)ofthe hypothalamus(Chrousos, 1992). The parvocellular corticotropin-releasing
hormone(CRH)and arginine-vasopressin are secreted and released in the hjqjophyseal
portal system where it can act on the anterior lobe ofthe pituitary gland(Lamberts et al,
1984; Vale et al, 1981). The PVN has neurons that project to the median eminence where

a hypophyseal system of capillaries transports CRH in the vascularized anterior pituitary
gland(Tumbull and Rivier, 1999). CRH is a 41-amino acid peptide that drives the

adrenocorticotropic hormone(ACTH)secretion and synthesis (Vale et al, 1981).
Arginine-vasopressin has little secretagogue activity, it acts as a synergistic factor for
CRH activity at the pituitary level. In normal conditions, when there is no stress, CRH is

released in a pulsatile fashion resulting in a diumal rhythm peaking in the early hours of
the moming and nadir during the first few hours of sleep (Tumbull and River, 1999;

Tsigos and Chrousos, 2002; Horrocks et al, 1990). The circadian changes are influenced
by a variety offactors, such as lighting, activity, and stress. CRH binds to its G-protein
coupled receptor on the corticotrope cells ofthe anterior pituitary lobe to stimulate the
, synthesis of proopiomelanocortin(POMC),the ACTH precursor(Tumbull and Rivier,
1996; Tumbull and Rivier, 1999). ACTH is then secreted in the systemic circulation, and

binds to its receptor, also G-protein coupled, in the zona fasciculata ofthe adrenal cortex.
The downstream signaling pathway of ACTH receptor activation leads to the synthesis
and secretion of glucocorticoids in the blood (Ottenweller and Meier, 1982). In humans
the major glucocorticoid is cortisol, and in rodents it is corticosterone. Glucocorticoids

are the final effectors ofthe HPA axis that control a variety of physiological functions.
These include the immune response, cardiac output, and metabolism, all of which
participate in maintaining homeostasis (Pratt, 1990). Glucocorticoids also interact with

the pituitary gland and the hypothalamus in the classical feedback endocrine system, to
terminate the stress response by inhibiting the synthesis of CRH and ACTH.

Steroidogenesis

Glucocorticoids are products of steroidogenesis, the biological process where
steroids are generated from cholesterol. When ACTH binds to its receptor the

melanocortin receptor-2, a G-protein coupled receptor, it activates adenylyl cyclase,
which will increase cyclic(cAMP)(Mountjoy et al, 1992; Liakos et al, 1998). The
increase ofintracellular cAMP will activate protein kinase A(PKA), which will release
its catalytic subunit and activate the cAMP response element binding protein(CREB)
(Svm et al, 2003). CREB will then activate the transcription, and translation ofthe

steroidogenic acute regulatory (Star) protein responsible for the rate-limiting step of
steroidogenesis: transporting cholesterol from the outer to the inner mitochondrial
membrane(Manna et al, 2002; Rainey et al, 2004). Once in the mitochondria, the

cholesterol is cleaved by cytochrome P450 enzyme (Privalle et al, 1983). Through a
series of hydroxylation mediated by enzymes located in the smooth endoplasmic
reticuliun and mitochondria, cortisol and corticosterone are synthesized. Once secreted in

the circulatory system, it then exerts its physiological function by activating its
ubiquitous glucocorticoid cytoplasmic receptor, a 94 kDa polypeptide (Smith and Toft,
1993; Pratt, 1990).

Glucocorticoid Functions

The binding of glucocorticoids to the glucocorticoid receptor will cause it to
phosphorylate and translocate to the nucleus, where it interacts with glucocorticoid
responsive elements (Pratt, 1990). This will lead to the repression or activation,
transcription, and translation of genes, which will cause pleiotropic physiological effects
(Scheinmann et al, 1995). The effects of glucocorticoids target metabolism, arousal,
cognition, development, and the immune system.
Glucocorticoids, as the name suggests, is involved in glucose metabolism

(Chrousos, 2000). Extra-hepatical amino acids are mobilized as a response to increased

circulating glucocorticoids and used as substrate for gluconeogenesis(Tsigos et al, 1997).
The increase of glucocorticoids will inhibit glucose uptake and induce insulin resistance
(Tsigos and Chrousos, 2002). Chronic activation of stress will eventually increase
visceral adiposity, decrease lean body mass, and suppress osteoblastic activity (ibid).

These effects can become clinically problematic for diseased patients, who may be
subjected to a stressor whether physiological or emotional.

Events associated with strong emotions or deemed stressful are often clearly

remembered by the subjects who experienced it. This "flash bulb" memory ofthe event is
attributed to the action of glucocorticoid on hippocampus, amygdala, and frontal lobes

(Cabill and McGaugb, 1999). The effect of glucocorticoid on cognitive performance and
memory is substantiated by extensive animal research (ibid). However the effects of
glucocorticoid follow an inverted-U-sbape dose response curve(Lupien et al, 2007). Too
much glucocorticoid and too little will lead to poor memory consolidation, and will
inhibit the retrieval of previously stored information(de Quervain et al, 1998).
Glucocorticoids are also critical for lung maturation and development(Olson et
al, 1979). This rings particularly true for preterm infants. Premature babies do not have

adequate surfactant in their lungs, which is necessary to decrease the air-liquid surface
tension interface (Bolt et al, 2001). Due to this insufficiency, these infants are at
increased risk for respiratory distress syndrome(Crowley,2000). If the respiratory
distress syndrome is treated with long term mechanical ventilation it can lead to
broncbopubnunary dysplasia(Nortbway et al, 1967). These conditions are treated with
synthetic glucocorticoids to increase surfactant production. However, as previously

mentioned, glucocorticoids increase glucose synthesis, and reduce its uptake, therefore
some side effects include byperglycemia, hypertension, inhibition of somatic growth and
a myriad of other physiological changes(Halliday and Ehrenkranz, 2000). Although
beneficial for lung maturation, the detrimental effects of chronic administration of

glucocorticoids may outweigh the benefits.

In addition to their effects on memory, glucose metabolism, and development,

glucocorticoids are well characterized for their immune suppressing capabilities
(Franchimont, 2004). Glucocorticoids have been in use for over half a century to treat
inflammatory and autoimmxme diseases (ibid). This class of hormones suppresses cellular
immunity, and promotes humoral immunity. Although the anti-inflammatory effects of
glucocorticoids are reported in the peripheral system, this effect does not translate to the
CNS.In fact, it is reported to exacerbate injury and increase inflammation after a
neuronal insult (Sorrells et al, 2009). The activity of HPA axis after a cerebrovascular
event, and the effect of glucocorticoid after such a stressor do not align with its antiinflammatory properties.

Glucocorticoids and Brain Injury
Recent advances reveal that glucocorticoids are detrimental to neuronal repair
and survival after an insult(Sapolsky, 1999; Dinkel et al, 2003). Notably, it is shown to

increase pro-inflammatory cytokines, induce apoptosis, and increase neurotoxicity(Caso
et al, 2007; Macpherson et al, 2005; Zoloaga et al, 2011; Arya et al, 2006). It was further
demonstrated that treatment with the rodent specific glucocorticoid, corticosterone,
worsened hippocampal neurons after global ischemia(Sapolsky and Pulsinelli, 1985). It

appears that glucocorticoids have opposite effects in the CNS. This raises the question

whether these reports found in adult studies are true to neonatal models of brain injuries.
Studies have shown that administering a synthetic glucocorticoid, dexamethasone,

before a hypoxic-ischemic event in neonatal rats is beneficial(Feng et al, 2011; Ikeda et
al, 2005; Felszeghy et al, 2004; Ekert et al, 1997; Tuor et al, 1996). However,these

studies overlook that most incidences of HI can occur in utero, thus making the time of
occurrence difficult to detect(Perlman, 2006). Particularly since these studies suggest
that the protective effects only are seen when dexamethasone is administered at least 6
hours prior to the insult. Because synthetic glucocorticoid administration has not

previously been investigated in neonatal HI after the insult, it is highly probable that posttreatment, may result in hyperglycemia, hypertension, and decrease of somatic growth as
reported in preterm infants treated for bronchopuhmmary dysplasia (Halliday and
Ehrenkranz, 2000). Also, since glucocorticoids are the last effector ofthe HPA axis it

may be likely that agonizing an already stressed HPA with dexamethasone could prove
detrimental.

The HPA activity is increased after a cerebrovascular event. Numerous studies
focusing on the pituitary-adrenal response show that ACTH and corticosterone is

upregulated after HI and that inhibiting glucocorticoid synthesis can reduce brain damage
(Krugers et al, 1998; Krugers et al, 2000). Clinical studies have also shown that

glucocorticoids reduce cerebral cortical grey matter volume(Murphy et al, 2001), and
impair long-term neuromotor and cognitive fimction(Yeh et al, 2004). Understanding the
implication ofthe last effector ofthe HPA axis is clinically paramount since synthetic
glucocorticoids are often administered systemically in premature infants. The hormones

ofthe HPA axis appear to be beneficial or detrimental within certain confines and

limitations warranting a better understanding of its regulation and modulation. A recent
report showed that a neuroprotective agent widely used in the clinic for hematopoietic

purposes, could modulate the levels of ACTH and corticosterone in naive adult rats
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(Mucha et al, 2000). This promising nenroprotective drug is granulocyte-colony
stimulating factor(G-CSF).

Granulocyte-Colony Stimulating Factor(G-CSF)
Fimctions of G-CSF

G-CSF is a glycoprotein with a molecule: weight of 19 kDa produced by a wide
range of cells including bone marrow cells, fibroblasts, and endotbelial cells(Demetri

and Griffin, 1991). It is a bematopoietic growth factor that initiates proliferation,
differentiation, and proliferation of granulocytes(Nicola, 1990). The G-CSF protein is

encoded by a single gene located on chromosome 17 ql 1-12(Solaroglu et al, 2006; Le
Beau et al, 1987). G-CSF confers its action by activating its receptor(G-CSF-R), a
transmembrane protein ofthe class I cytokine receptor family(Bazan, 1990). The
receptor has an immunoglobulin-like domain, a cytokine receptor-homologous domain
and three fibronectin type III domains in the extracellular region(Fukunaga et al, 1991).
The downstream signaling pathway of G-CSF-R activation include the Janus Kinase
(JAK)/ signal transducer and activator of transcription(STAT),the Ras/mitogenactivated protein kinase(MAPK)and the phosphatidylinositol 3-kinase(PI3K)pathway
(Tian et al, 1994; Shimoda et al, 1997; Ward et al, 2000). G-CSF-R is expressed on a
myriad of cells including those in the CNS; neurons, glial cells, and endotbelial cells

(Demetri and Griffin, 1991). The cloning of G-CSF established its clinical application
were it is now commonly used to treat chemotherapy-induced neutropenia(Schneider et
al, 2005; Neidhart et al, 1989). The wide use of G-CSF for bematopoietic recovery has
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made this drug potentially translatable to neurological brain injury, particularly since its
pharmacokinetic profile is well known.

Neuroprotective Capabilities of G-CSF
Numerous studies give account of G-CSF as a neuroprotective agent(Solaroglu et
al, 2006; Schabitz et al, 2010; Popa-Wagner et al, 2010). It was first investigated in vitro

where it protected neurons from glutamate-induced cell death (Schabitz et al, 2003).
Furthermore, it was shown to be upregulated in the penumbra after an ischemic insult
(ibid; Kleinschnitz et al, 2004). This suggests that the organism has a compensatory
response to increase endogenous neuroprotective proteins. Other studies using various
models of brain injury reported that G-CSF reduced infarct volume, mortality, brain

edema, and apoptosis (Six et al, 2003; Park et al, 2005; Whalen et al, 2000). It was
postulated that G-CSF may confer its protective properties by increasing neutrophils in
addition to activating its receptor in the CNS. However, reports have shown that the

increase of neutrophils or bone marrow stromal cells do not improve neurological
function after a brain insult(Chopp and Li, 2002; Hudome et al, 1997). Therefore

suggesting that neutrophil increase is not involved in G-CSF induced neuroprotection.
Additionally, it was further demonstrated that 5 daily doses of G-CSF(50 pg/kg)

improved neurological behavior 28 days after ischemia, as measured by cognitive and
sensorimotor tests(Gibson et al. 2005; Fathali et al, 2010). The protective properties of
G-CSF are pleiotropic as it was demonstrated that it could improve neural plasticity and
vascularization, reduce pro-inflammatory cytokines, and protect against excitotoxicity
(Zavala et al, 2002; Schabitz et al, 2003; Shyu et al, 2004). In light ofthese observations.
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G-CSF has promising therapeutic potential due to its multimodal effects. Whether these
results translate to the pediatric population is questioned since these studies were mostly
conducted in adults. Although cues are taken from the vast body of literature of adult
ischemic injury, the nature of neonatal injury is substantially different(Vannucci,2007).

The brain ofterm infants is susceptible to injury in areas of high metabolic demands, and
high density of excitatory neurons(Takeoka et al, 2002). Preterm infants sustain a more
severe injury because oftheir vniderdeveloped circulatory system (ibid). Therefore to
adequately assess the therapeutic potential of G-CSF in the pediatric population,
specifically low birth weight and premature infants, age appropriate animal models are
required.
G-CSF has shown promise in neonatal studies where it protected the brain from

apoptosis, increased development, and improved neurobehavioral outcomes(Yata et al,
2007; Fathali et al, 2010). There is one study conducted by Schlager and colleagues,

which shmys that G-CSF did not improve neurobehavioral outcomes or brain injuries
(2011). The contradicting results reported by Schlager and colleagues could be attributed
to their experimental design. They used 4 times the dose reported in previous studies, and
administered the drug 60 hours after the initial insult whereas other studies started
therapy as early as 1 hoiu* after the insult(Yata et al, 2007; Fathali et al, 2010). All things

considered, the dearth oif neonatal studies looking at G-CSF after HI indeed shows an
area meriting scientific exploration.
The mechanism of G-CSF action remains to be adequately elucidated. The

evidence that G-CSF may modulate(ACTH)and glucocorticoids in naive rats(Mucha et
al, 2000)suggests that it has a probable interaction with the neuroendocrine system.
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These hormones are effectors ofthe HPA axis, which are reported to play a critical role
in ischemic brain injury. Determining if G-CSF regulates these hormones in a neonatal
model with a different HPA response than adults, after a diseased state known to increase
HPA activity warrants much needed examination.

Significance of Studies

The complexity ofthe neurodevelopmental sequelae of HI necessitates a drug
with multimodal properties. Therefore, to address the limitations clinically observed for
the treatment of HI, we propose to study for the first time the interaction between a

hematopoietic neuroprotective growth factor, G-CSF, with the neuroendocrine pituitaryadrenal activation in a neonatal model of HI brain injury. G-CSF and its mechanistic
properties on the HPA axis have not previously been studied in a neonatal HI model.
Furthermore, the effects of G-CSF on infarct volume have not previously been reported
in neonates. The novel theoretical concept that this study sets forth will challenge the
clinical practice paradigm that administers synthetic glucocorticoids to pre-term neonates
with high propensity to HI complications. Equally important, is the fact tiiat no previous
reports examined the mechanism of G-CSF on steroidogenesis. For this purpose, our
proposed investigation will add fundamental information that may guide future research

in a wide range of directions. Particularly since G-CSF is already in clinical use for
neonatal neutropenia, this compound can feasibly be introduced into practice for neonatal
neuroprotection (Schlager et al, 2011; Kuhn et al, 2009; Carr et al, 2003). Herein lies the
novelty where we aim at investigating the mechanism of G-CSF via the HPA effector
hormone, corticosterone, in a rat neonatal model of HI.
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The supposition that G-CSF may influence glueoeorticoid synthesis is highly
probable due to its ability to activate class I cytokine receptors(Aritomi et al, 1999).
Class I cytokine receptors are transmembrane proteins expressed on the surface of cells
including the steroidogenic adrenal cortical cells(Hoggard et al, 1997; Malendowicz et
al, 2003). Studies have shown that class I ejdokine receptor ligands, such as leptin, can
inhibit corticosterone synthesis in vitro(Hsu et al, 2006; Salzmann et al, 2004). Because
G-CSF and leptin share sequence homology, we propose that G-CSF may inhibit

glueoeorticoid synthesis. No previous reports indicate that the G-CSF receptor is
expressed on adrenal glands; therefore we postulate that its activity is via the cjdokine

family receptor. Also, a variety ofintracellular cascades activated by G-CSF decrease
apoptotic markers easpase-3 and Bax (Solaroglu et al, 2009); these intracellular cascades

are also regulated by glueoeortieoids. Based on this evidence our central hypothesis is
that is that G-CSF will protect the neonatal brain from apoptosis bv suppressing the
activity ofthe pituitarv-adrenal response via the activation of its cvtokine receptor after
HL

Approach of Studies
The rationale ofthis study is that identifying the mechanisms involved in G-CSF

therapy for neonates will extend into adequately designed clinical applications for infants

victimized by HI. We plan to achieve the goal ofthis study with the following aims
which is summarized in a schematic diagram (Figurel.1).
AIM 1:Evaluate the anti-apoDtotic properties ofG-CSF via the vituitarv-adrenal axis
after neonatal HL
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Because reports indicate that glucocorticoids can exacerbate apoptosis we

hypothesize that G-CSF reduces brain infarct and does so by inhibiting corticosterone
synthesis.
AIM 2:Determine the mechanism bv which G-CSF inhibits corticosterone synthesis in
vitro.

We hypothesize that G-CSF activates class I C5dokine receptors on the adrenal
glands which reduces corticosterone. This study will be conducted in well-characterized
rodent Y1 adrenal cortical cells.
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AIM 1

AIM 2

AGTH-R
Class I cytokine receptor

Adrenal cortical cells

cAMP

4r

ABBREVIATIONS:

ACTHrAdrenpcprlicotropic hormone
Akt: protein kinase B :

Bax: Bci-2 associated X protein
: Bcl-2: B cell lymphohia 2
cAMP:cyclic adenosinerhdnpsphosphate
0-CSF: Grahulocyte-cplony stjrnplating factor
JAk2: Janus kinase 2
PDE3B: Phosphodiesterase 3B

P|3K: phdsphbinositide3 kjnase
Figure 1,1. Scheinatic representation of tlie central Hypothesis and specific ainis
Aim 1 as illustrated in blue will investigate the effect of G^CSF on corticosterone

synthesis /«: v/vo after neohatal Hi, measure the apoptotic markers in the brain and assess
ihfarct volume, Aini 2 (black) will study the effect of G-GSF in vrVro on corticosterone

Synthesis. This aiiii propos;es that G-CSF' activates the JAK2/PI3K/il^t/PDE3B signaling
pathway
to
inhibit
corticosterone
synthesis
by
degrading
cAMP
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Abstract

Several reports indicate that the activity ofthe hypothalamic-pituitary-adrenal

axis(HPA)is increased after a brain insult and that its down-regulation can improve
detrimental outcomes associated with ischemic brain injuries. Granulocyte-colony
stimulating factor(G-CSF)is a neuroprotective drug shown in the naive rat to regulate
hormones of the HPA axis. In this study we investigate whether G-CSF confers its
neuroprotective properties by influencing the HPA response after neonatal hj^oxiaischemia(HI). Following the Rice-Vannucci model, seven-day old rats(P7) were
subjected to xmilateral carotid ligation followed by 2.5 hours of hypoxia. To test our
hypothesis, metyrapone was administered to inhibit the release ofrodent specific
glucocorticoid, corticosterone, at the adrenal level. Dexamethasone, a synthetic
glucocorticoid, was administered to agonize the effects of corticosterone. Our results
show that both G-CSF and metyrapone significantly reduced infarct volume while
dexamethasone treatment did not reduce infarct size even when combined with G-CSF.

The protective effects of G-CSF do not include blood brain barrier preservation as
suggested by the brain edema results. G-CSF did not affect the pituitary released
adrenocorticotropic hormone(ACTH)levels in the blood plasma at 4 hours, but
suppressed the increase of corticosterone in the blood. The administration of G-CSF and

metyrapone increased weight gain, and significantly reduced the Bax/Bcl-2 ratio in the
brain while dexamethasone reversed the effects of G-CSF. The combination of G-CSF

and metyrapone significantly decreased caspase-3 protein levels in the brain, and the
effect was antagonized by dexamethasone. We report that G-CSF is neuroprotective in
neonatal HI by reducing infarct volume, by suppressing the Hl-induced increase ofthe
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Bax/Bcl-2 ratio, and by decreasing corticosterone in the blood. Metyrapone was able to
confer similar neuroprotection as G-CSF while dexamethasone reversed the effects of GGSF. In conclusion, we show that decreasing HPA axis activity is neuroprotective after
neonatal HI, which can be conferred by administering G-CSF.

Introduction

Neonatal hypoxia ischemia(HI)remains the leading cause of perinatal brain
injury, which ultimately leads to cerebral palsy, mental retardation, and epilepsy
(Vannucci et al, 1999). It is a major public health concem with a prevalence of60% in
preterm infants and an incidence of 1-8 cases per 1000 births(Vannucci, 2000). In spite
ofits critical mortality and morbidity rate, current therapeutic avenues are still lacking;
thus necessitating alternative strategies to amplify ciirrent therapeutic potential.

Several reports suggest that the activity ofthe hypothalamic-pituitary adrenal(HPA)axis
is increased after HI, and that its down-regulation can reduce brain damage(Krugers et
al, 1998, Krugers et al, 2000). HPA axis activation involves the upregulation of the

adrenocorticotropic hormone(ACTH)and glucocorticoids. ACTH is released from the

pituitary gland in the blood stream where it acts on the adrenal glands to induce synthesis
and release of glucocorticoids. Glucocorticoids are reported to play an important role in
neurological function (Sorrells et al, 2009; Dumas et al, 2010), and neuronal damage in

the hippocampus after ischemic insults(Roy and Sapolsky, 2003). Studies have shown

that supraphysiological levels of glucocorticoids can exacerbate excitotoxic effects
(Stein-Behrens et al, 1992), elevate levels ofreactive oxygen species(Mclntosh and

Sapolsky, 1996), and increase neuroinflammation and apoptosis(MacPherson et al, 2005;
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Kuchinsky and Gillardon, 2000). This is of clinical relevance, since synthetic

glucocorticoids are often administered systemically in premature infants(Thebaud et al,
2001). Clinical studies have shown that premature infants treated with synthetic
glucocorticoids have reduced cerebral cortical grey matter volume(Murphy et al, 2001),
and impaired long-term neuromotor and cognitive function(Yeh et al, 2004).
Accordingly, targeting the HI induced elevation of glucocorticoids may be a promising
therapeutic target.

A promising stroke drug candidate, granulocyte-colony stimulating factor(G-

CSF), has been shown to modulate ACTH and glucocorticoids in rats(Mucha et al,
2000). G-CSF is a glycoprotein, and a growth factor known to confer neuroprotection in

various models of brain injury(Yata et al, 2007; Popa-Wagner et al, 2010). It is currently
in Phase II clinical trial for adult ischemic stroke, and well tolerated at high doses
(Schabitz et al, 2010). In various animal studies, G-CSF has been reported to have antiapoptotic, anti-inflammatory, excitoprotective, and neurotropic properties (Solaroglu et
al, 2006, Gibson et al, 2005; Schabitz et al, 2003; Konishi et al 1993). Furthermore, it has

shown promise in neonatal HI studies where it protected neurons from apoptosis, and
improved long term neurobehavior outcome(Yata et al, 2007; Fathali et al, 2010). A
variety ofintracellular cascades activated by G-CSF decrease apoptotic markers caspase3, Bax (Solaroglu et al, 2009); these intracellular cascades are also regulated by

glucocorticoids. Whether G-CSF confers its neuroprotective effects through the HPA axis
in neonatal HI has yet to be determined.

On the basis ofthese observations, we hypothesize that G-CSF attenuates

apoptosis partially by down-regulating the activity ofthe HPA axis. Herein we chose to
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focus on the pituitary-adrenal response by measuring ACTH and rodent specific

glucocorticoid, corticosterone. To test this hypothesis we used metyrapone, an inhibitor
of glucocorticoid synthesis, which suppresses circulating levels corticosterone.
Metyrapone reduces corticosterone production by inhibiting the 11-P hydroxylation of
11-deoxycorticosterone. In addition, we used dexamethasone, a synthetic glucocorticoid
that agonizes the effects of circulating corticosterone. Here we investigate whether GCSF reduces neuronal apoptosis partially by regulating the ACTH and corticosterone
response following experimental neonatal HI.

Materials and Methods

Animal Model

The Institutional Animal Care and Use Committee ofLoma Linda University
approved all the experiments used in this study. A modified Rice-Vannucci model was

used as previously described (Rice et al, 1981; Chen et al, 2009). In brief, SpragueDawley 7-day old rat pups(P7)underwent unilateral right common carotid ligation under
isoflurane anesthesia at 0300 hours. Because P7 rats do not have an established diurnal

rhythm of plasma corticosterone or ACTH,(Allen and Kendall, 1966; Leal et al, 1999)
we chose a time that was in the dark cycle consistent with the nocturnal activities of rats

(Levin and Levine, 1975). For consistent hormonal results, the ordered animals were
allowed 3 days to acclimate to the new facility and the surgeries were all conducted at the
same time. After recovery for 1 hour, the animals were placed in a hypoxic chamber

submerged in a 37°C water bath, subjected to 8% O2 balanced in N2for 2.5 hours. Sham
animals underwent anesthesia and neck incision, the carotid was exposed without the
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ligation and was exposed to normoxic conditions. All P7 rats were returned to their
mothers at the same time after hypoxic exposure.

Drug Administration
A total oftwo hxmdred and fourteen animals were used in this study. Sixteen

animals expired in the hypoxic chamber giving this study a mortality of 7.47 percent. The
remaining one hundred and ninety-eight animals were randomly divided into the
following groups: Sham (n=24), Vehicle (n=27), G-CSF 50|xg/kg (n=29), Metyrapone 10
mg/kg (n=8), Metyrapone 30 mg/kg(n=29), G-CSF + Metyrapone 30 mg/kg(n=27),
Dexamethasone 0.1 mg/kg (n=7), Dexamethasone 0.5 mg/kg(n=23), G-CSF +
Dexamethasone 0.5 mg/kg (n=24). The drugs were administered subcutaneously in a total
volume of30 pL one hour after hypoxia.

Blood and Collection

Blood was sampled 3 hours after drug administration and 24 horns after HI.

Briefly the animals were deeply anesthetized with isoflurane, and the blood was collected
via cardiac piuicture with a 22-gauge needle. Blood was transferred in EDTA coated
tubes, and centrifuged at 3,000 rpm for 5 minutes. Blood plasma was immediately

removed and stored at -80°C until assayed(Mucha et al, 2000).

Infarct Volume and Body Weight
At 24 hours, brains were collected and infarct volume was determined with 2,3,5-

triphenyltetrazoliumchloride monohydrate(TTC)(Sigma Aldrich, St-Louis, MO USA)
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staining and analyzed by Image J software as previously described(Zhou et al, 2009).
Briefly, the brains were sectioned in 2 mm slices, incubated in 2% TTC solution for 5
minutes in the dark, washed in phosphate buffered saline(PBS),and fixed in 10%
formaldehyde. The infarct volume was traced and analyzed with Image J Software

(Version 1.43u; National Institutes of Health, Bethesda, MD,USA). The animals were
weighed on a high precision balance before surgery and at 24 hours immediately before
being euthanized. The weight difference was calculated as(weight 24 hrs after HIweight before surgery).

Brain Water Content

Pups were euthanized 24 hours after HI and the brains were divided in three parts
(ipsilateral and contralateral hemispheres, and cerebellum). Each part was immediately

weighed (wet weight) on a high precision balance(Denver Instrument, sensitivity ±

0.001 g)and again after drying in a 100°C oven for 24 hours(dry weight) as previously
described(Chen et al, 2008). The percentage was calculated as [(wet weight-dry
weight)/wet weight] X 100.

Hormone Assay

ACTH was measured with a two-site enzyme-linked immunosorbent assay

(ELISA)kit(MD Bioproducts, St.-Paul, MN,USA)following the manufacturer's

protocol. This assay used a goat polyclonal antibody to ACTH,and a mouse monoclonal

antibody to ACTH that respectively bmmd the C-terminal(34-39)and the N-terminal of
ACTH (1-24). The minimum detection limit ofthe assay was 0.22 pg/mL.
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Corticosterone was measured with an ELISA kit(Enzo Life Sciences, Plymouth Meeting,

PA,USA)with a sensitivity of27.0 pg/ml according to the manufacturer's instructions.
[

Westem Blot

Animals were euthanized at 24 hours after HI. The brain hemispheres were

immediately collected and snap frozen in liquid nitrogen and stored at -80°C until
analyzed. Whole cell protein extracts were obtained from brain samples by homogenizing
in RIPA lysis buffer(Santa Cruz Biotechnology, Inc, Santa Cruz, CA,USA)and

centrifuging for 25 minutes in 4°C at 14,000 g. Ten percent SDS-PAGE gels were used,
and 50 mg of denatured protein extracts were loaded in each well. The gel was
electrophoresed and transferred to a nitrocellulose membrane(Bio-Rad, Hercules, CA,
USA). The membrane was blocked with 5% non-fat blocking grade milk(Bio-Rad)and
probed with appropriate dilution of primary antibody overnight. The following primary
antibodies used were: cleaved caspase-3(Santa Cruz Biotechnology, 1: 1000), Bax (Cell

Signaling Technology, Danvers, MA,USA, 1:1000), Bcl-2(Cell Signaling Technology,
1:1000), and actin(Santa Cruz Biotechnology, 1:1000). After washing the membranes

three times, they were probed with specie-specific secondary antibodies(Santa Cruz
Biotechnology) at 1:1000 dilutions for 1 hour at room temperature and visualized using
ECL Plus, Chemiluminescence(GE Healthcare and Life Sciences, Piscataway, NJ). The

optical densities ofthe bands were analyzed with Image J Software (Version 1.43u;
National Institutes of Health, Bethesda, MD)and normalized to actin as the loading
control.
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Statistical Analysis

The results are presented as the mean ± standard error mean(SEM). Statistical
differences among groups were analyzed by using one-way analysis of variance
(ANOVA)followed by the Tukey multiple comparison test(Graph Pad Prism Version
5.0d). Probability value<0.05 was considered statistically significant.

Results

Determining the Optimal Dose of Metyrapone and Dexamethasone
The metyrapone clinical dose for adrenal insufficiency is 30 mg/kg(Giordano et
al, 2008)hence the starting dose of choice. We used two doses 10 mg/kg and 30 mg/kg to
determine which dose would optimally reduce infarct volume compared to the control
groups. Dexamethasone on the other hand has previously been studied in neonatal HI
using the two following doses: 0.1 mg/kg and 0.5 mg/kg(Tuor et al, 1993,Ikeda et al,
2002). However,these reports use dexamethasone as pretreatment, our study will use it as

post-treatment. Our infarct volume results indicate that metyrapone reduces the infarct
volume in a dose dependent manner and the effect is significant with the 30 mg/kg
dosage (Figure 2.1). The vehicle group has a mean of29.42% ± 3.40 and metyrapone 30
mg/kg significantly reduced the infarct percentage to 16.08% ± 2.57(p<0.01vs HI

+Vehicle). The administration of dexamethasone did not significantly reduce infarct
volume when compared to vehicle; low dose (0.1 mg/kg) mean infarct percentage was
23.99% ± 1.25 and high dose (0.5 mg/kg)was 27.69% ± 1.69(Figure 2.1).
Dexamethasone 0.5 mg/kg produced a significantly larger infarct volume compared to
that produced by metyrapone 30 mg/kg treatment(p<0.05)(Figure 2.1). Based on these
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Figure 2.1 Doise responses of metyfapohe and dexamethasone. Representative
TTC stained coronal braiii section of the dose response analysis for metyrapone^

(MET) and dexamethasone (DE;X) at 24 h. (* = p < 0.0i vs Vehicle, # = p<0.05

s

MET 30 mg/kg, all HI ^oups p < 0 01 ys Sham). Each line on the left hand side of
the brain imajges deinarks 1 mm.
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results metyrapone 30 mg/kg and dexamethasone 0.5 mg/kg were considered as the
appropriate dosages for all the following experiments and molecular studies. The F value
for the

ANOyA analysis conducted is 22 36.

Infarct Volurne
Weight after G-CSF, Metyrapone
ime and B
and Dexamethasone Adtniniistratiion

The administration of G-CSP(50 mg/kg) 1 hour after Hi was able to significantly

reduce infarct percentage at 24 hOurS from 29,42% ± 3.40 to 14.70% ± 3.63(p<0.05 vs.
HI + Vehicle, Figure 2.2A). Metyrapone(30 mg/kg)and the Metyrapone + G-CSF
groups similarly conferred neuroprotection by significantly reducing infarct volume
compared to the Vehicle group to 16.08% ± 2.57 and 15.08% ± 3.47 respectively (p<0.05
vs. HI -H Vehicle).Furthermore, agonizing the HPA axis with dexamethasone (0.5 mg/kg)

admMstration did not significantly affect infarct volume compared to the Vehicle group
(27.69% ± 1.69 infarct percentage) and G-CSF lost its neuroprotective effect when coadministered with dexamethasone yielding an infarct percentage of26 36% ±2.78
(Figure 2.2A).
Since a characteristic of HI injury is weight loss(Chen et al, 2011), the weight
difference at 24 hours after HI was measured. The sham

animals gained a mean weight of

2.11 g ± 0.22 after 24 hours while the HI vehicle treated pups lost an average 0.78 g ±

0.42. The animals treated with G-CSF lost 0.63 g ± 0.49 and the group treated with

metyrapone lost 1.07 g ±0 26 which were not significantly different compared to the
vehicle treated group. Co-administration of G-CSF and metyrapone significantly reversed
the

weight loss compared to all the other HI groups, the animals gained 1.25 g ± 0.39
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Infarct Valume 24 hours post^HI
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HI). (* - p < 0.01 vs Vehicle, # ^ p < 0.05, ** = p < 0.001 vs Sham, ## = p < 0.01 vs

MET + G-CSF). Each line on the left hand side of the brain images demarks 1 mm
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(P<0.01, Figure 2.2B). The adiiiinistratipn Of dexaraelhasone significantly exacerbated
weight loss coihpared to vehicle treated group by losing a mean 2.73 g ± 0.23 (p<0.01,
Figure 2.2B). Even when co-administered with G-GSF,the animals lost a mean of2.14 g

± 0.42(Figure 2.2B). All the groups that underwent HI significantly lost weight
+ G-;GSF + Metyrapone group,

Brain edema was assessed by measuring brain water cbntent, which was elevated
m

(Figrire 2.3). G-GSF did riot significantly reduce brain edema, but was significantly
different than the dexamethasbne treated group (p<0,01), which ako had elevated bram
edema wheri compared to Sham (p<0;01). Dexamethasone iricreased brain water coritent

eyeri when cb-administered with G-GSF(p<0.05 vs. Sharn). The admiriistration of
riietyrapone alope orin combmation with G-GSF did not significantly alter bram water
content No significant chatiges in the brain w:ater content amongst all the groups were

observed in the contralateral hemisphere and the cerebellum (Figure 3):
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Figure 23. Brain water content after G-GSF, metyrnpone, and dexamethasone

treatment after HI. QuantificatiQn of brain water content 24 h after HI in the
cerebellum, contralateral, and ipsilateral brain hemisphere. Brain water content was
markedly increased by HI + Vehicle, DEX and DEX + G^-CSF treated groups;

(* = p < 0.05). No significance Was observed in G-CSF, MET and MET + G-CSF. DEX
treated group had higher brain waiter content thain the G-CSF treated;group(## = p<0.05
YS G-CSF). No significmt difference Was observed ampngst the groups in the cerebellum
; and contrala;teral heniispbere.
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ACTH Blood Plasma Level 4 Hours and
24 Hours after HI

The ACTH level in the blood was increased after HI(p<0,05 yS. Sham), and
adrninistering G-GSF did not influence ACTH levels(Figure 2-4A). The administration
of metyfapone increased ACTH levels, while dexamethasone significantly reduced it as a

result of both dnigs interfering with die negative feedback niechanism ofthe HPA axis
i^<0.01)(Figure 2.4A). At 24 hours,;no significant differences were observed amongst
all the groups(Fig 2.4B).

Corticosterone Blood Plasma Level 4 Hours and
24 Hours after HI

The levels of corticpsterone in the blood significantly increased after HI, and the
adhiiniStration of G-C

corticosterone levels while the administration of dexamethasone alone or in combination

with G-CSF increased corticosterone levels 4 hours after HI. At24 hours, corticosterone

levels decreased in all

that had G-CSF in

their treatrhent regime:n had iower Corticosterone levels than their control groups(Figure

2.5B), The dexamethasonb+G-CSF group had significantly lower corticosterone levels
than the dexamethasone treated group.
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Figure 2,4 AGTH blood plasma levH 4 h and 24 h afterTH, A. At 4 h, ACTH levels

were significantly increased by III (* = p < 0.05 vs Sham). MET and MET + G-CSF

groups ha^d markedly increased ACTH level Compared to Vehicle (##■- p < 0.05). DEX

and DEX+ G-GSF had significantly decreased ACTH levels Compared to MET and
MET + G-CSF groups (# !^ p < 0.01 vs MET 30 mg/kgi **:" p < 0.01 vs MET + G-CSF)
B. ACTH blood plasma level is normalized to Sham at 24 h after HI.
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Figure 2,5 Gorticosterone blood plasma level 4 h and
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Apoptotic Markers Expression in the
Brain After Treatment

The western blot results indicate that G-CSF reduced pro-apoptotic marker Bax
(Figure 2,6A), and increased Bel-2(Figure 2.6B)in the ipsilateral hemisphere, however
the data did not yield statistical significance. HI induced an increase in the Bax/Bcl-2

ratio (p<0;05); this ratio was significantly lowered by the treatment of G-CSF,
05):(Figure 2.6C). The
Hl-induiced iricrease of cleaved caspase-3 was significantly reduced by the combination
of G-CSF and metyrapone treatment. Ddxarnethasone and dexamethaspne + G-CSF co^
treatment fiirther increased cleaved caspase-3 levels(p<0.05 vs. Sham, p<0.05 vs.

MET+G-CSF)
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Discussion

In the present study, we show that targeting the elevation of corticosterone in the
blood with G-CSF and met5U*apone can protect the neonatal brain from HI injury,
increase development, and reduce apoptosis. We also show that administering

dexamethasone after HI impairs development, and worsens apoptosis. These results
support the hypothesis that elevated corticosteroids are deftimental to the functioning and
recovery of neurons after an insult(Tombaugh and Sapolsky, 1992; Mclntosh and
Sapolsky, 1996).
G-CSF reduced infarct volume 24 hours after HI, and metyrapone similarly

reduced infarct volume. When G-CSF was co-administered with metyrapone, no further
reduction on infarct size was observed. As metyrapone could not potentiate the lowering
effect of G-CSF on the infarct volume it may be probable that both G-CSF and

met5n'apone share a common mechanism of neuroprotective action. However this remains
to be elucidated. We postulate that the combination of G-CSF-i- metyrapone maximally
reduced the progression of HI in the penumbra where milder injury is sustained as

detected by TTC for that specific time point of24 hours. Because HI injury is more
severe and necrotic at its core (Nakajima et al, 2000; Pulera et al, 1998), the necrotic cells
have been irreversibly damaged and are beyond rescue. The penumbra,the area

surroimding the ischemic core, is not exposed to the same intensity of energy failure;
these neurons are in a critical stage where they can be recovered. It is with that premise
that combined therapy, may have maximally rescued the cells in the penumbra but could
not reverse the damage caused at the core. Although no synergistic effect was observed in
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the infarct volume analysis, the animals treated with G-CSF and metyrapone gained
weight in comparison to all the other groups that were subjected to HI.
When the activity of corticosterone was agonized with dexamethasone no
difference in infarct voliune was detected when compared to the Vehicle treated group.
The protection observed with G-CSF treatment was completely lost when combined with
dexamethasone. This result suggests G-CSF may also exert its protection through
lowering the corticosterone level. This data is of extreme importance since multiple
reports suggest that dexamethasone treatment is neuroprotective in HI studies(Feng et al,
2011; Ikeda et al, 2005; Felszeghy et al, 2004; Ekert et al, 1997; Tuor et al, 1996). In

those reports, dexamethasone was administered before inducing experimental HI. Since
most incidences of HI can occur in utero thus making the time occurrence difficult to
detect(Worle et al, 1984; Perlman,2006), the translatability ofthese findings are
extremely difficult. Especially since pretreatment would imply indentifying children who
are at risk for hypoxia ischemia, which is difficult to assess(Perlman,2006; Butt et al,
2008). Additionally, a long-term study reports that preterm infants treated with
dexamethasone for bronchopulmonary dysplasia or chronic lung disease (Halliday et al,
2009) were at increased risk for cerebral palsy and adverse neurological effects, all of
which are outcomes caused by HI(Volpe, 2001; Vannucci et al, 2000). Although pre

treatment of dexamethasone does reduce HI injury and facilitates extubation,(Tuor et al,

1995; Davis et al, 2000), it could be detrimental for proper neurological development in
preterm infants. Our results show that dexamethasone administration after HI does not
reduce infarct volume, and fiirther exacerbates development as indicated by weight loss.
If G-CSF were to be administered clinically in a preterm child, the administration of
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dexamethasone may antagonize its effects. This postulate would require human studies to
be authenticated.

The oceurrenee of apoptosis prevails in the penumbra where milder injury has
been sustained after the HI insult(Pulera et al, 1998). Apoptosis peaks from 24-72 hours;
since its oceurrenee is delayed, it is an important and suitable target for treatment. Our
results show that the expression of apoptotic markers are influenced by the hormones

involved in the pituitary-adrenal response. The Bax/Bcl-2 ratio was significantly lowered

by the administration of metyrapone alone and G-CSF. Additionally, the combined GCSF + metyrapone treated group had significantly lower caspase-3 than G-CSF and

metyrapone alone. These results suggest that the synergistic effect of both drugs could be

attributed to other pathways all directed at lowering easpase-3. When dexamethasone was
administered, higher expression of easpase-3 was observed, thus inferring that the
progression ofthe disease is worsened by dexamethasone administration.

The pathophysiology of HI also involves an increased vascular permeability,
which leads to brain edema. It is well documented clinically that the administration of

corticosteroid can reduce brain edema(Betz et al, 1990 stroke; Heiss et al, 1996). The
integrity ofthe blood brain barrier is usually compromised within hours ofischemie
injuries(Zhang et al, 2000). Administering corticosteroid to target brain edema has been

shown to reduce the pathological sequelae involved in brain swelling(Fishman, 1982).
Our results however indicate that brain edema is significantly increased when
dexamethasone 0.5 mg/kg is administered. The contradiction of our results to what is

typically observed elinieally could be due to the inverted-U shape dose effect curve of
eortieosteroids (Baldi and Bueherelli, 2005). The non-linear effect of cortieosteroids
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ought to be considered when interpreting our results. Understanding the exact dose

response of dexamethasone and treatment in neonatal hypoxia ischemia therapy for brain
edema is an area necessitating further studies. Also, whether targeting brain edema is

sufficient to reduce neuronal cell death in neonates is another area granting further

investigation. When it came to G-CSF and metyrapone,these drugs did not significantly
reduce brain edema. The interpretation ofthis data suggests that their mechanism of

action may not involve preserving blood brain barrier integrity.
It is clear that the pituitary-adrenal response is increased after HI, and that

modulating its effects may prove beneficial in reducing infarct volume in the acute phase
ofinjury. Considerable reports have shown that elevated plasma corticosterone can

exacerbate neuronal damage in adult brain injury models of HI(Krugers et al, 2000, Stein

and Sapolsky et al, 1988). Our results show that administering metyrapone reduced
corticosterone levels in neonates after HI, however the administration of G-CSF reduced

corticosterone levels more robustly as seen at the 4 hours time-point. At 24 hours, all the
animals that had G-CSF_in their treatment regimen had lower corticosterone levels than

their control group. What is perplexing is that ACTH levels were not affected by the
administration of G-CSF. This implies that G-CSF signaling is able to either directly
affect steroidogenesis at the adrenal level, or decrease the free corticosterone in the blood

by increasing corticosteroid-binding protein in the blood. It can be argued that G-CSF

affects the pituitary-adrenal response as a by-standard effect of its capacity to reduce

injury(Yata et al, 2007)and thus reducing the stress on the animal. However, we oppose
this precept since G-CSF did not affect ACTH levels. Furthermore a previous report has
shown that G-CSF can modulate the pituitary-adrenal response in naive rats(Mucha et al.
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2000). The mechanism by which G-CSF affects corticosterone level after HI should be a
new area of interest to further understand its application clinically.
We conclude that reducing Hl-induced corticosterone elevation with both G-CSF

and metyrapone reduces infarct volume, and pro-apoptotic markers. Additionally, the
nature of G-CSF neuroprotection may involve CORT suppression in the blood. We also
demonstrate that administering dexamethasone after HI exacerbated neuronal damage,
impaired development and apoptosis.
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Abstract

It has been reported that granulocyte-colony stimulating factor(G-CSF)

influences the activity ofthe hypothalamic-pituitary-adrenal(HPA)axis primarily via the
hormones adrecorticotropic hormone(ACTH)and glucocorticoids. Namely, G-CSF was
shown to inhibit corticosterone in rodents after a hypoxic-ischemic event; the rodent

specific glucocorticoid known to exacerbate injury after an insult. The manner in which
G-CSF interacts with corticosterone biosjmthesis remains to be examined. In this study,
we investigate for the first time the underlying mechanism of G-CSF on corticosterone

biosjmthesis in a rodent Y1 adrenal cortical cell line. Cholera toxin was used to agonize

corticosterone synthesis by constitutively increasing cyclic adenosine monophosphate
(cAMP). Corticosterone and cAMP were quantitatively assayed using a commercial
enzyme-linked innmmosorbent assay(ELISA). Janus Kinase 2

(JAK2)/Phosphatidylinositol-3-kinases (P13K)/Protein kinase B (Akt), the downstream
signaling components of G-CSF receptor activation, their phosphorylated forms and
Phosphodiesterase 3B(PDE3B)were detected by western blot. G-CSF at a low dose(30

ng/ml)inhibited corticosterone synthesis, but lost its inhibitory effect as you increased its
concentration. The inhibitory effect of G-CSF was conferred by interfering with the
cAMP signaling via the activation of JAK2/P13K/PDE3B pathway, as verified with

respective inhibitors. The degradation ofcAMP by G-CSF signaling reduced
corticosterone. We conclude that G-CSF mediates corticosterone synthesis inhibition at

the adrenal level via JAK2 activation ultimately degrading intracellular cAMP in Y1
cells.
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Introduction

Previous reports indicate that G-CSF, a neuroprotective and hematopoietic

protein, may be involved in regulating hormones ofthe hypothalamic-pituitary-adrenal
(HPA)axis, primarily adrenocorticotropic hormone(ACTH)and the rodent specific
glucocorticoid, corticosterone(Mucha et al, 2000; Charles et al, 2012). The paucity of
studies investigating the effect of hematopoietic growth factors on neuroendocrine

activity highlights an important area that necessitates investigation (Zylihska et al, 1999;
Tringali et al, 2007). Particularly in light of devastating clinical conditions that increase
HPA activity such as a cerebrovascular event(Charles et al, 2012; Weidenfeld et al,
2011; Krugers et al, 2000; Fassbender et al, 1994). Understanding how G-CSF influences
HPA activity may become a beneficial area of study, particularly when it can

downregulate the detrimental HPA activity reported in a rodent hypoxia-ischemia
neuronal injury model(Charles et al, 2012).

The results fi*om the previous reports suggest a probable relation and interaction
between G-CSF and the organs ofthe HPA axis. Starting with the adrenal gland, no
studies have demonstrated the direct effect of G-CSF on the adrenal cells involved in

steroidogenesis. Furthermore, the expression of the G-CSF receptor on adrenal glands has

not previously been reported. However,there are other reports illustrating that other

ligands such as erythropoietin and leptin, that have similar downstream signaling
pathways as G-CSF,interact with the HPA axis(Roubos et al, 2012; Hsu et al, 2006;
Tringali et al, 2007; Tokgoz et al, 2002). The supposition that G-CSF may influence
corticosterone synthesis is highly probable since its receptor belongs to a long chain
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helical cytokine family whose ligands have shown to influence steroidogenesis(Hiroike
et al, 2000; Mashbum and Atkinson, 2008; Hsu et al, 2006). The Janus Kinase 2(JAK2)/
phosphatidylinositol-3-kmases(PI3K)/ protein kinase B(Akt)signaling pathway has
been shown to inhibit steroidogenic products in cell culture models, and regulate
steroidogenic proteins transcription and translation (Lefrancois-Martinez et al, 2011; Li et
al, 2003; Hsu et al, 2006). In light ofthese observations, it is highly probable that G-CSF
may exert its steroidogenic influences similarly.
At the adrenal level, steroidogenesis occurs in adrenal cortical cells, and is
initiated by ACTH which increases the intracellular level ofits second messenger cyclic
adenosine monophosphate(cAMP)(Rainey et al, 2004; Cooke, 1999). In the widely used
Y1 rodent adrenal cortical cell line, steroidogenesis can be initiated by any stimulant of
cAMP production such as cholera toxin (Forti et al, 2002; Yasumura et al, 1966). The

induction ofcAMP production leads to the activation of protein kinase A (PICA)
ultimately leading to steroidogenesis(Lin et al, 1995; Lopez et al, 2001; Clark et al,
2000). Previous reports have shown that JABC2 activation can suppress steroidogenesis by
inhibiting its upstream regulator cAMP with phosphodiesterase 3B(PDE3B)(Hsu et al,

2006; Johnsen et al, 2009). Additionally, we have previously shown that G-CSF can
reduce corticosterone after neonatal hypoxia-ischemia (Charles et al, 2012). Whether G-

CSF influences the steroidogenic process initiated by cAMP through JAK2 activation in

an adrenal cell culture model has yet to be explored.
In light ofthese observations, we propose to study for the first time the effects of
G-CSF on steroidogenesis in YI adrenal cortical cells. We hypothesize that G-CSF
mediates corticosterone synthesis inhibition on Yl cells by activating the
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JAK2/PI3K/Akt/PDE3B pathway. We will use cholera toxin to constitutively increase
cAMP production, and test our hypothesis by inhibiting the JAK2/PI3K/PDE3B pathway
with appropriate inhibitors. We will investigate the mechanistic effect of G-CSF on
cAMP and corticosterone production.

Material and Methods

Cell Culture

Rodent Y1 adrenal cortical cells(ATCC,Manassas, VA)were grown in F12K
medium(ATCC)supplemented with 2.5% fetal bovine serum(ATCC),15% horse serum

(Fisher Scientific, St-Louis, MO),and 1% penicillin/streptomyciu(Thermo Scientific,

Rockford,IL), as a monolayer in a humidified atmosphere at 37°C in 5% CO2in T75
flasks(BD Biosciences, San Jose, CA). Medium was changed every 4 days, and cells
were sub-cultured after 8 days and split to a 1:3 ratio. The cells were stored in liquid
nitrogen(5% dimethyl sulfoxide(DMSO)growth medium)or plated for experiments. All
experiments were conducted in passage 4 - passage 6 cells. Cells were counted using the

Tcio™ Automated Cell Coimter(Bio-Rad Life Science, Hercules, CA)and seeded in 12
well plates at a concentration of 1 X 10^ oflive cells/well. The cells were grown in 2 ml
of growth media/well for 48 hours. The cells were immediately serum starved for 8 hours
as previously described(Calejman et al, 2011)and subsequently incubated with growth

medium for 24 hours containing the appropriate chemicals for the respective groups.
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Chemicals and Treatment

Cholera toxin, the JAK2 inhibitor Tyrphostin AG490(AG490),the PI3K inhibitor
LY-294002, and the PD3B inhibitor 3-isobutyl-l-methylxanthine(IBMX)were
purchased from Sigma-Aldrich (St. Louis, MO). The inhibitors AG490,LY-294002, and

IBMX were respectively diluted in DMSO for stock solutions of Img/ml,5 mg/ml, and
0.5 M.G-CSF receptor chimera(Fc Chimera Active) was purchased from Abeam
(Cambridge, MA)and G-CSF was obtained from Loma Linda University Pharmacy. The
following concentrations were used: cholera toxin(50 ng/ml)(Hsu et al, 2006), AG490
(50 pM)(Chen et al, 2005), LY-294002(20 pM)(Williams et al, 2010),IBMX(10 pM)
(Montero-Hadjadje et al, 2006). A dose response for G-CSF (30,100, 300 ng/ml)(Hsu et
al, 2006)and the G-CSF receptor chimera(10, 30,100 ng/ml) after cholera toxin
treatment was conducted. At 24 hours, growth media were collected from each well for
subsequent assay and analysis. G-CSF treated cells were collected at the following time
points after the initiation oftreatment: 0,5,15, 30,60,120 minutes to determine the
activity ofthe JAK/PI3K/Akt/PDE3B pathway.

Cell Viability Assay

At 24 hours post-treatment, growth media were removed from each well and the

cells were trypsinized. Trypan Blue Cell Exclusion was used to determine cell viability
which was assayed and recorded using the TCIO Automated Cell Counter Cell Viability
analysis and protocol(Bio-Rad).
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Corticosterone and cAMP Quantitative Assay

Corticosterone was measured in the growth media 24 hours after treatment(Astort
et al, 2009, Calejman et al, 2010)using a commercial enzyme-linked immunosorbent
assay(ELISA)kit(Enzo Life Sciences, Farmingdale, NY). The minimum detection limit
ofthe assay was 27.0 pg/ml. A 1:20 dilution ofthe media was assayed according to the
manufacturer's instructions. After 2 hours oftreatment(Hsu et al, 2006), growth media
were removed and hydrochloric acid was added to the cells to stop the activity of

phosphodiesterases. The levels ofcAMP were quantitatively analyzed using a
colorimetric competitive ELISA kit(Enzo Life Sciences) with a sensitivity of0.30
pmol/ml.

Western Blot

Cells were washed with phosphate buffered saline(PBS)and incubated in 100 pi
of RIPA cell lysis buffer(Santa Cruz Biotechnology,Inc., Santa Cruz, CA)for 20
minutes. Cells were snap-frozen in liquid nitrogen, thawed, and centrifuged at I25g for
10 minutes. The supernatant was collected, and assayed for protein concentration using
the spectroscopic Bradford protein Assay (Bio-Rad). Approximately 30 pg of proteins

were electrophoresed in 10% SDS-PAGE gel, and transferred on a nitrocellulose

membrane(Bio-Rad). The membrane was blocked with 5% non-fat blocking grade milk
(Bio-Rad)and probed with a 1:1000 dilution of primary antibody overnight. The
following antibodies were used: G-CSF receptor(Abeam), JAK-2(Abeam), phosphor-

JAK2(Abeam),P13K(Cell Signaling Technology, Danvers, MA),phosphor-P13K(Cell
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Signaling Technology), Akt(Cell Signaling Technology), phosphor-Akt(Cell Signaling
Technology),PDE3B(Abeam),and actin (Santa Cruz Biotechnology). After washing the

membranes three times, they were probed with a 1:1000 dilution secondary antibodies
(Santa Cruz Biotechnology)for the specie ofthe primary antibody for 1 hour at room
temperature. The protein bands were visualized with ECL Plus, Chemiluminescence(GE

Healthcare and Life Sciences, Piscataway, NJ). The densities were analyzed using Image
J Software (Version 1.43u; National Institutes of Health, Bethesda, MD)and normalized
to actin.

Statistical Analysis

The data are presented as the mean ± standard error mean(SEM). One-way
analysis of variance(ANOVA)followed by post-hoc Tukey multiple comparison test was
used. A probability value < 0.05 was considered statistically significant.

Results

G-CSF Influences Cholera Toxin-Induced Steroidogenesis via its
Own Receptor on Y1 cells

The expression ofthe G-CSF receptor has not previously been reported in adrenal
cells. Therefore, its expression was first investigated with western blot. Our results

indicate that the G-CSF receptor protein is expressed in Y1 cells (Figure 3.1 A)
suggesting its function on adrenal cortical cells. The administration of cholera toxin
significantly(p<0.001)increased the steroidogenic product of corticosterone 5 times the
percentage ofthe vehicle group (Figure 3.IB). G-CSF administration with cholera toxin
inhibited corticosterone synthesis at the low dose of 30 ng/ml(p<0.05 vs. cholera toxin)

54

but lost its inhibitory property as you increased the dose to 100 and 300 ng/ml(Figure
3.IB). The concentration of cholera toxin +G-CSF 300 ng/ml was significantly increased
compared to cholera toxin + G-CSF 30 ng/ml(p<0.05). To determine if G-CSF receptor

activation was responsible for the inhibitory effect observed on corticosterone synthesis,
the cells were incubated with cholera toxin + G-CSF + G-CSF Receptor Chimera(10,30,

100 ng/ml). The inhibition of corticosterone synthesis was lost when the G-CSF receptor
chimera was added (Figure 3.1C). The inhibitory effect reached significance at 30 ng/mL.
In light ofthe objective ofthis study, G-CSF 30 ng/mL was used for subsequent
molecular assays and hormone analysis.
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Figure 3.1. G-CSF influences cholera tojunrinduced steroidogeneisis via its own
receptor on Y1 cells. A) G^CSF receptpr is expresised in Y1 adrenal cortical cells. B) G-

"GSFsii"
dose 30

ng/ml but loses its inbilbitory property at 100 and 300 ng/ml. G-CSF 30 ng/ml

does not affect basal corticpsterone

syiitheSis. N=8/ group C) The addition of the G-CSF

receptor chitnera reversed the inhibitory effect of G-CSF and reach significance at 100

ng/ml, #=p<0.01 vs Vehicle, * = p<0.05 vs CTX ** '^<0.05 vs CTX + G-CSF 30 ng/ml
■ N=6/gro]
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downstream signaling(Nakainae-Akahori et al, 2006; Schneider et al, 2005). Whether

ng/ml) was administered and protein expression ot"JAKi2,PI3K and Akt as well as their

phosphorylated active fprni were analyzed 0,5,15, 30,60,120 minutes after treatment
initiation.

did not reach significance (Figure 3,2B). The increase oftotal JAK2 after G-CSF
treatment significantly peaked 30 mmutes after treatment(p<0.05 vs.0 minutes). The

minutes aftOr treatment(phosphOr-PI3K/total PI3K)(p<0.05 vs. 0 minutes. Figure 3.2C).

.05 vs. 0

treatment arid increased 5 minutes after treatment(p<0.05 vs 0 minutes)(Figure 3.3.)
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via the

JAK2/PI3K/PDE3B Pathway
To determine whether JAIC2/PI3K and the dbwnstreani eleinent PI)E3B is

mvolved in G-CSF inhibition of corticosterdne synthesis, JAK2 inhibitor AG490,PI3K
inhibitor LY-294002 and PDE3B inhibitor IBMX were added to cholera toxin + G-GSF
30 ng/ttiL treatrnent. Additionally, since the inhibitors were dissolved in DMSO,a

control group DMSG (0.2%)was added for coinparative analysis. DMSO 0.2% did riot

increase corticosterone synthesis compared to control group. The addition of each
inhibitor in coiribination with cholera toxin + G-CSF'30 ng/nil to themedia blunted the

inhibitory effect of G-CSF corticosterone synthesis(p<0.05 vs. cholera toxin + G-CSF 30

ng/mL)(Figure 3 4A)- Corticosterorie was significantly highei(p<0.05)ill the media of
cells in the following groups cornpared to cholera toxin + G-CSF 30 ng/ml

cholera toxiii.

cholera toxiri + G-CSF 30 lig/iriL + AG490, cholera toxin + G-CSF 30 ng/ml+ LY

294002, c;holera toxin + G-CSF 30 ng/riiL + IBMX. The admniistration Ofthe drugs did

not sign;ificantly affect the cell viability as assessed with Trypan Blue Cell Exclusion

(Figure 3.4B)
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3.4. G-GSF iiihihils

cUnHcosterone synthesis viia the JAK2/PI3K/PDE

pathway. A) The JAK2 inhibitor (AG490), PI3K inhibitor (LY-294002), and PDE
inhibitor(IBMX) significahtly reverse the corticdsterone inhibition confeired by G-CSF
On chdiera toxin-induced steroidogenesis (p<0;05 vs CTX + GTCiSF i30 ng/ml). The
treatment with DMSO (0.2%), G-CSF 30 ng/ml, AG490, LY-294002, IBMX alone did
not significantly affect basal corticosterone synthesis compared to Control group. B)
treated group is not
significantly different. N=6/group.
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G-CSF Inhibits Cholera Toxin-ihduced cAMP

Upregulation via JAK2/PT3K/PDE3B
The primary fuhction of phosphodiesterases is to cleaye the phbsphodiester bond

ofcAMP,the primary tnessenger and mediator of sterbidogenesis (Meshats et al, 2002).
The measure ofcAMP was asseissed two hours after initiating treatment as previously

described(Hsu et al,2'006)

Cholera toxin treatment increased cAMP significantly

cpthpared to Control treated cells from 3.85 ±0.20 pmol/L to 22.2 ± 2.84 pniol/ml
(p<0.01 vs. Control and DMSO)(Figure 3.5). G-CSF administration alone did not

significantly affect cAMP levels compared to Cohtrpl and DMSG treated cells. The

combination of cholera toxin + G-CSF 30 ng/ml si^ificantly reduced the cholera toxin
induced upregulation from 22,2 ± 2.84 pmol/mL to 14.47 ±0.60 pmol/mL(Figure 3.5).
The:inhibition of JABv2 with AG490 in the cholera toxin + G-CSF 30 ng/ml + AG490

treated cells significantly antagonized the inhibitory effect of G-CSF (p<0.01 vs. cholera

tPxin + G-CSF 30 ng/mL), the average eoncentration was 24 83 ± 2.60 pmol/mL.
Inhibitihg PI3R with LY-294002 in the cells treated with cholera toxin + G-CSF 30
ng/ml yielded a cAMP level of 19.18 ± 1.38 pnioi/inL; significantly higher than cells

without:LY-294002 in the growth medium (p<0.01 vs. cholera toxin + G-CSF 30
ng/mL). The inhibition ofPDE3B with IBMX substantively and significantly increaised
cAMP levels in cells treated with cholera toxin + G-CSF to 61.15 ± 27.08 pmol/mL

(p<0;01 vs. cholera toxin + G-CSF 30 ng/mL). All the inhibitors reversed the G-CSF
reduction ofcAMP levels in cholera toxin treated cells. Treatment withG-CSF 30

ng/mL and the inhibitors alone did not significantly change cAMP levels when compared
to control and DMSO treated cells.
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Figure 3,5i GrCSF abates cholera toxiii-induced cAMP upregulation via the

JAK2/PI3K/PDii pathway. GTX significantly increased cAmP levels from 3.85 ± 0.20

pmol/l to 22.20 ± 2:84 prnpFriil (p<0.001 vs Control and DMSO (0.2%)). G.GSF

decreased the upregulation of cAMP to 14.47 ± 0.60 prnoPrnl which was antagonized by

Uddihg to the treatment the JAK2, PI3K, arid PDE inhibitor (AG490, LY-294002,
TBMX). The treatment with DMSO (0.2%), G-GSF 30 ng/ml, AG490, LY-294002, and
IBMX alone did not significantly affect basal cAMP. N= 6/group.
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Discussion

In this current study we investigated for the first time the direct effect of G-CSF
on adrenal steroidogenesis and explored the probable mechanism by which G-CSFinduced inhibition of steroidogenesis. Thereupon we examined the involvement of GCSF in a well characterized rodent Y1 adrenal cortical cell line on steroidogenic

products. We show that G-CSF at 30 ng/mL inhibits cholera toxin induced corticosterone
synthesis and cAMP upregulation. We also report that the G-CSF receptor is expressed in
Pv

adrenal cortical cells and by co-administering G-CSF with its G-CSF receptor chimera
the inhibitory effect against cholera toxin is lost. Additionally, we demonstrate that G-

CSF activates the JAK2/P13K/Akt/PDE3B pathway in adrenal cells which is responsible
for the inhibition ofcAMP and steroidogenic signaling components and product hence
blunting corticosterone biosynthesis.

We first determined whether G-CSF receptor protein was expressed in the adrenal
cortical cells as no previous reports indicated the latter. Since our results show that the G-

CSF receptor was expressed, a dose response using G-CSF was conducted to determine
its influence on the glucocorticoid involved in HPA activity in rodent corticosterone. Our
results show that G-CSF inhibits corticosterone synthesis at low dose(30 ng/mL), but as

you increased the concentration the inhibitory effect was lost. We postulate that this
phenomenon is probably a result of non-genomic effects due to the saturation ofthe GCSF receptor. Hence other signaling pathways could be activated to oppose the inhibitory
effect or drive steroidogenesis. Based on the premise that increasing G-CSF
concentration reverses the inhibition, it is probable that increasing the concentration

beyond the ones used for this study could potentially increase steroidogenesis. This
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explanation would help reconcile the results of Mucha and colleagues(2000)indicating
that G-CSF increases corticosterone blood plasma level after chronic administration in
naifve rats. However,this remains to be elucidated.

The inhibitory effect of G-CSF was modulated by the activation of its receptor as
the addition ofthe G-CSF receptor chimera at various concentration resulted in an
increased corticosterone product(Figure 3.1C). For the first time, we show that G-CSF
has direct interaction with cells of an HPA organ. This is of critical importance primarily

if the effect can potentially cause adverse or beneficial therapeutic effects in a clinical
setting.
Since G-CSF is known to activate JAK2/PI3K/Akt in other tissues(Nakamae-

Akahori et al, 2006)and that PBK/Akt is upstream to PDE3B,we measured the total and
activated forms of JAK2/PI3K/Akt and the expression ofPDE3B over two hours after GCSF treatment initiation. Our results indicate that JAK2 phosphorylation increased over

two hours as did the total form of JAK2. Total JAK2 protein expression significantly
increased and peaked 30 minutes after treatment initiation. The activated forms ofPI3K,
and Akt also increased over two hours peaking from 15-30 minutes, but unlike JAK2 the
total forms ofPI3K and Akt expression were not affected. G-CSF also increased PDE3B
over the 120 minutes time course which peaked at 5 minutes. These results show that the

JABC2/PI3K/Akt activation of G-CSF is preserved in rodent adrenal cortical cells.
The corticosterone measurements indicate that G-CSF inhibits cholera toxin via

the JAK2/PI3JC/PDE3B pathway since the addition ofthe inhibitors in the treatment
reversed its inhibitory effect. Therefore, this suggests that the pathway may be involved
in cortieosterone synthesis inhibition. To verify that the differences reported amongst
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each treated groups were not due to cell viability, Trypan Blue Exclusion was used. The
results indicate that no significant difference was observed in cell viability amongst the

groups. Therefore, the observed effects in corticosterone synthesis and other molecular
events were attributed to the drugs influence on signaling pathways and not cell viability.
The elevation ofcAMP observed two hours after the initiation oftreatment with

cholera toxin was inhibited by G-CSF. This report suggests that the activation of
JAK2/PI3KyPD3B by G-CSF inhibits steroidogenesis by reducing cAMP levels.
Furthermore, the inhibitors of JAK2/PI3K/PDE3B individually reverse the inhibition of
cAMP levels. The levels of cAMP were further increased when treated with cholera toxin

+ G-CSF 30 ng/mL -i-IBMX compared to cells treated with cholera toxin alone. This
occurrence may be a result ofinhibiting the basal levels ofPDEs, which are activated by
steroidogenic signaling(Mehats et al, 2002). Steroidogenesis can initiate other signaling
pathways such as calcium signaling whose downstream event includes the activation of
PDEs(ibid). Therefore IBMX may inhibit the basal activity ofPDEs, which would
attribute to the higher cAMP levels.

Conceming the limited studies that look at G-CSF and HPA activity, one in naive
rats and one after hypoxia ischemia, one must understand the complexity of what is at
hand. Markedly, the putative ability of G-CSF to influence HPA activity ought to be

investigated also at the pituitary level and at the hypothalamic level. Reports have
indicated that other hematopoietic growth factors with similar signaling pathways can

inhibit corticotropin-releasing hormone(CRH)which is responsible for ACTH synthesis
at the pituitary level (Tringali et al, 2007;Zylinska et al, 1999). In light of our previous

report(Charles et al, 2012)indicating that ACTH was not increased in spite of
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corticosterone inhibition, one must consider the delicate negative feedback and the

probable interaction of G-CSF with the pituitary gland. This perplexing result puts in
question the negative feedback which should have shown an increase of ACTH as a result
of corticosterone inhibition. Therefore it is probable that G-CSF may have direct effects
on each organ ofthe HPA axis. Determining the manner in which G-CSF influences HPA
activity in a naive model and after a diseased state merits further exploration.

In conclusion, we demonstrate that G-CSF has non-hematopoietic function in the
HPA axis by regulating steroidogenesis in the Y1 adrenal cortical cell line. G-CSF was
able to abate the upregulation of cholera toxin-induced cAMP via the
JAK2/PI3K/Akt/PDE3B pathway which ultimately inhibited the steroidogenie product of
corticosterone. We propose that a better understanding ofthe manner in which G-CSF
has neuroendocrine properties may better translate its efficacy in a clinical setting,
particularly when investigating diseases that involve the over-activation ofthe HPA axis.
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CHAPTER FOUR

DISCUSSION

How the activity ofthe HPA axis and its relation to G-CSF therapy reflect on
pathophysiological outcomes of HI was not previously investigated. For that reason, the
underlying foundation ofthis scientific initiative was to investigate the latter. We show
for the first time that the neuroprotective properties of G-CSF depend on its inhibition of

corticosterone synthesis. Furthermore, we demonstrate for the first time that G-CSF has
direct effects on steroidogenesis by activating its receptor on adrenal cortical cells. These
findings bifurcate om current knowledge of G-CSF function, similarly to when G-CSF
was first discovered to he neuroprotective.

G-CSF was first reported almost a decade ago,to have neuroprotective properties
in brain injury models such as stroke by activating its receptor in the central nervous

system(CNS)(Schabitz et al, 2003; Gibson et al, 2005). It was joining the ranks of
another hematopoietic factor known to have modalities in the brain after injmy,
erythropoietin(Masuda et al, 1993; Digicaylioglu et al, 1995). Subsequent studies that

emerged from this discovery have shed light on its multimodal properties that span across
a multitude of brain insults(Park et al, 2005; Ren and Finkelstein, 2005; Schneider et al,

2005). The numerous reports have indicated G-CSF as an angiogenic, neurogenic, antiinflammatory, and anti-apoptotic agent(Shyu et al, 2004; Gibson et al, 2005; Komine-

Kobayashi et al, 2006; Schneider et al, 2005; Solaroglu et al, 2009, Strecker et al, 2010).
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Currently it is in Phase n clinical trial for adult ischemic injury where it is well tolerated
at high doses(Schabitz et al, 2010). In addition to its promise in adult studies reflecting
similar injury as that seen in neonates, age appropriate animal models of HI also indicate
that G-CSF improves outcome after the insult(Yata et al, 2007, Fathali et al, 2010,
Charles et al, 2012). G-CSF was once unrecognized for its function in the CNS,and we

now show that its properties extend beyond its direct neuroprotective effects as illustrated
in stroke studies. Unknowingly, G-CSF had properties that influenced a very dynamic
and delicate neuroendocrine system, the HPA axis(Mucha et al, 2010).

There are numerous areas of HI pathophysiology that are still not investigated in
neonates as it pertains to HPA activity after a brain insult. However,indices can be

retrieved from other models indicating that high levels of glucocorticoids were associated
with poor outcome(Feibel et al, 1977; Krugers et al, 1998; Stein-Sapolsky, 1988). In the
adult HI injury model, results indicate that HPA overactivation in the acute phase was
detrimental and its down-regulation led to improved neurological outcome (Krugers et al,
2000; Smith-Swintosky et al, 1996). We measured for the first time the hormones of
ACTH and corticosterone in a neonatal HI model and indicated that G-CSF conferred its

properties by significantly decreasing corticosterone. Using metjo^apone, the inhibitor or
corticosterone, and dexamethasone, a sjmthetic steroid that agonized the effects of
corticosterone, we showed that regulation of pituitary-adrenal activity is of critical

importance in G-CSF therapy. Especially since agonizing corticosterone led to impaired
development, and increased pro-apoptotic biomarkers even when co-administered with
G-CSF. Dexamethasone was administered after the insult, which was different from other

studies administering it hours prior to HI in neonates(Tuor et al, 1993; Ikeda et al, 2002).

73

This difference yielded opposite effects. Pre-treatment with dexamethasone appears to be
protective, while our data show that post-treatment exacerbates injury. Why posttreatment of dexamethasone is detrimental in contrast to pre-treatment is an area that

remains to be elucidated; particularly when it comes to its co-administration with G-CSF.
This difference in pre and post-treatment could be owed to the intact versus disrupted
BBB,especially since dexamethasone does not cross an intact BBB.Hence its
exacerbation ofinjury could be attributed to its effect in CNS, while the protective effects

could be due to its impact in the periphery. This fact would need to be substantiated with
adequate HI studies. With attention to the hormone results, metyrapone and
dexamethasone show that the negative feedback in neonates in responsive. This finding
suggests that elements ofthe HPA axis are functional in the neonatal rat after HI. For this
reason, the suggestion that neonates have a hyporesponsive HPA axis needs to be
examined, particularly in the context of a cerebrovascular event(Tu et al, 2006). Overall,

the hormone data ultimately led to the question of how G-CSF inhibited corticosterone
synthesis? The analysis ofthe data immediately pointed towards G-CSF having a
probable direct interaction with the adrenal gland ofthe HPA axis.
The initial step was to determine whether the G-CSF receptor was expressed on
adrenal cortical cells. We identified for the first time the expression ofthe G-CSF

receptor on rodent adrenal cortical cells suggesting its direct effect on HPA activity. The
results we reported were perplexing as they were interesting. It was interesting since GCSF was shown to inhibit corticosterone synthesis. However this was true only at a low

dose. It became perplexing when at higher doses G-CSF lost its inhibitory properties. The

span of concentration that was utilized only covered so much ground. Therefore, one
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must wonder, whether high doses of G-CSF could do the exact opposite? If this were the
ease then the study of Mucha and colleagues would be explained (2000). Particularly
since they report that chronic administration of G-CSF increased ACTH and
corticosterone in naive rodent models. Whether this is a matter of alternate signaling

pathways or saturation of G-CSF receptor activation remains to be investigated.
Understanding the mechanism of G-CSF signaling as it pertained to
corticosterone inhibition is primordial to establish how the two components interrelate.
Since the receptor was expressed on a different cell t5qpe, we verified whether the
JAK/PI3K/Akt signaling was conserved. Our data indicate that the pathway is preserved
in adrenal cortical cells, and that it is responsible for the inhibitory proponent of G-CSF
activity on corticosterone synthesis.

Clinical Significance

The current therapeutic avenues of HI are extremely limited. Only hypothermic
therapy has shown a confined ammmt of success(Koenisgberger et al, 2000). There is a
plethora of determining factors including a paucity of adequate mechanistic animal

studies that halt the progress of promising drugs in the clinical setting. The complexity of
this issue contributes to the grim prognosis of HI patients. These patients are primarily

premature infants, and since the development of premature babies differ from term
babies, oxn study utilized a model reflective ofthat population. Can G-CSF uphold the
promise that our animal studies suggest in the clinic? Perhaps. However one must
consider the multiple physiological and molecular mechanisms that are activated by GCSF. Particularly, when it comes to its inhibitory properties on steroidogenesis. Our

75

results show that co-administering G-CSF with dexamethasone does not protect the brain
ofthe animal from injury(Charles et al, 2012). In fact, it worsened development and
apoptosis (ibid). Scientifically this supported our hypothesis, but it challenges the
translatability of G-CSF. Here is why. Preterm infants often have developmental, and
lung maturation complications which are clinically treated with synthetic glucocorticoids
(Davis et al, 2001). If G-CSF were studied in a human clinical trial, the co-administration

of synthetic glucocorticoid would impair its neuroprotective ability as our data suggest.
This devastating outcome could lead clinicians to prematurely overlook the promise of GCSF. This could lead to a misguided conclusion, when ultimately the synthetic
glucocorticoid commonly found in the treatment regimen of premature infants is what

diverged the action of G-CSF. This study shows that in the acute phase, synthetic
glucocorticoids are detrimental. This is substantiated by a longitudinal study in which

preterm infants were at increased risk for cerebral palsy and adverse neurological effects

when treated with synthetic glucocorticoids, all of which are outcomes caused by HI '
(Volpe,2001; Vannucci et al, 2000). Nonetheless, because G-CSF potentially could
increase glucocorticoid long-term, it could potentially facilitate extubation by
endogenously increasing glucocorticoids(Mucha et al, 2000). This remains to be verified
with animal and human studies.

G-CSF has an excellent safety record, and a well-known pharmacological profile

due to is clinical use for neutropenia and bone marrow harvesting (Schneider et al, 2005;
Neidhart et al, 1989; Morstyn et al, 1989). This advantage makes its translatability
propitious. Additionally, its multimodal properties suggest that it can target the multiple
facets of HI pathophysiological sequelae. Therefore, if it were to transition into clinical
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trial for preterm infants, it could potentially be promising. The only caveat would be to
consider the use of synthetic glucocorticoids to maximize the promise of G-CSF.

Future Directions

Our study focused on two general areas: the effect of G-CSF after HI on the

synthesis of pituitary-adrenal axis hormones, and the mechanism by which it confers its
effect. We approached the first part of our study by investigating the effect of G-CSF on
pituitary-adrenal hormones as it pertained to apoptosis. Since glucocorticoids can also
affect inflammation, and glutamate excitotoxicity after a neuronal insult, these areas

merit further exploration(Dinkel et al, 2003; Goodman et al, 1996). Also, our study only
investigated the effect of G-CSF in the acute phase. How chronic administration of G-

CSF affects the pituitary-adrenal axis hormones long-term needs to be explored. The
neurobehavioral outcomes, brain atrophy, angiogenesis, and neurogenesis should also be
evaluated at long-term time points; particularly as in regards to dexamethasone, and

metyrapone administration. Additionally, an adequate dose response for G-CSF and its
effect on corticosterone should be investigated. Especially since the in vitro studies show
that higher doses of G-CSF lost its inhibitory property. Not to mention, that a study using
higher dose of G-CSF(200 pg/kg)did not protect the brain from neonatal HI injury,

compared to our lower dose(50 pg/kg)(Schlager et al, 2011; Charles et al, 2012).
Determining how this occurs and whether this effect is dependent on corticosterone is
essential to harness the fixll therapeutic promise of G-CSF.
In addition to the neuroprotective effect of G-CSF, G-CSF influences the

hormones ofthe neuroendocrine system. Our study focused on the direct interaction of G-
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CSF on the adrenal gland ofthe HPA axis, but many other areas have yet to be
investigated. There are cues from other studies showing growth factors or hormones with
similar signaling cascade that exert effect ofthe HPA-axis. Therefore there is a high
probability that the actions of G-CSF extend beyond the adrenal gland. Perhaps G-CSF
controls the activity of the HPA axis at the level ofthe hypothalamus and/or the pituitary

gland. The details ofthis possible interaction should be considered for subsequent
studies.

Conclusion

G-CSF has pleiotropic physiological effects, and we demonstrate that its

neufoprotection is dependent on its direct interaction with the HPA axis. We show that
G-CSF inhibits corticosterone synthesis, and protect the neonatal rat brain from HI injixry,
by reducing infarct volume and reducing pro-apoptotic markers. Agonizing the effects of
the HPA axis with a synthetic glucocorticoid exacerbated injury even when coadministered with G-CSF. This study highlighted a novel function of G-CSF,since it
inhibited the Hl-induced upregulation of corticosterone. We foimd that the G-CSF
receptor was expressed on adrenal glands and conferred its inhibitory effect on
corticosterone synthesis by activating the JAK2 signaling pathway. Future studies are
needed to better understand the interaction with G-CSF and the HPA axis. Nevertheless,

the promising therapeutic potential of G-CSF should continue to be pursued in
I

subsequent preclinical stroke research.
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